Literature DB >> 32663057

Efficacy of immune checkpoint inhibitors in different types of melanoma.

Ernesto Rossi1, Giovanni Schinzari1,2, Brigida Anna Maiorano2, Giulia Indellicati1, Alessandro Di Stefani3, Monica Maria Pagliara4, Simona Maria Fragomeni5, Erika Valentina De Luca6, Maria Grazia Sammarco4, Giorgia Garganese5,7, Jacopo Galli8, Maria Antonietta Blasi4,9, Gaetano Paludetti8, Giovanni Scambia5,10, Ketty Peris3,6, Giampaolo Tortora1,2.   

Abstract

Immunotherapy can be used for cutaneous, mucosal, uveal and conjunctival melanoma. Nevertheless, we cannot expect the same benefit from checkpoint inhibitors for all the types of melanoma. The different biological features can explain the variable efficacy. The main results obtained with immune checkpoint inhibitors in the various types of melanoma were reviewed.

Entities:  

Keywords:  Immunotherapy; conjunctival melanoma; melanoma; uveal melanoma

Year:  2020        PMID： 32663057      PMCID： PMC7872095          DOI： 10.1080/21645515.2020.1771986

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  83 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.

Authors:  Ester Simeone; Antonio Maria Grimaldi; Lucia Festino; Diana Giannarelli; Vito Vanella; Marco Palla; Marcello Curvietto; Assunta Esposito; Giuseppe Palmieri; Nicola Mozzillo; Paolo Antonio Ascierto
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

3.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors:  Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal:  N Engl J Med       Date:  2018-04-15       Impact factor: 91.245

4.  Incidence of noncutaneous melanomas in the U.S.

Authors:  Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

5.  The efficacy of anti-PD-1 agents in acral and mucosal melanoma.

Authors:  Alexander N Shoushtari; Rodrigo R Munhoz; Deborah Kuk; Patrick A Ott; Douglas B Johnson; Katy K Tsai; Suthee Rapisuwon; Zeynep Eroglu; Ryan J Sullivan; Jason J Luke; Tara C Gangadhar; April K S Salama; Varina Clark; Clare Burias; Igor Puzanov; Michael B Atkins; Alain P Algazi; Antoni Ribas; Jedd D Wolchok; Michael A Postow
Journal:  Cancer       Date:  2016-08-17       Impact factor: 6.860

6.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

7.  Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Authors:  Paolo Antonio Ascierto; Pier Francesco Ferrucci; Antoni Ribas; Rosalie Fisher; Michele Del Vecchio; Victoria Atkinson; Henrik Schmidt; Jacob Schachter; Paola Queirolo; Georgina V Long; Anna Maria Di Giacomo; Inge Marie Svane; Michal Lotem; Gil Bar-Sela; Felix Couture; Bijoyesh Mookerjee; Razi Ghori; Nageatte Ibrahim; Blanca Homet Moreno
Journal:  Nat Med       Date:  2019-06-06       Impact factor: 53.440

8.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

9.  The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis.

Authors:  Simon J Furney; Samra Turajlic; Gordon Stamp; J Meirion Thomas; Andrew Hayes; Dirk Strauss; Mike Gavrielides; Wei Xing; Martin Gore; James Larkin; Richard Marais
Journal:  Pigment Cell Melanoma Res       Date:  2014-06-30       Impact factor: 4.693

10.  Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Authors:  James Larkin; David Minor; Sandra D'Angelo; Bart Neyns; Michael Smylie; Wilson H Miller; Ralf Gutzmer; Gerald Linette; Bartosz Chmielowski; Christopher D Lao; Paul Lorigan; Kenneth Grossmann; Jessica C Hassel; Mario Sznol; Adil Daud; Jeffrey Sosman; Nikhil Khushalani; Dirk Schadendorf; Christoph Hoeller; Dana Walker; George Kong; Christine Horak; Jeffrey Weber
Journal:  J Clin Oncol       Date:  2017-07-03       Impact factor: 44.544
View more
  7 in total

1.  Editorial of special focus on melanoma immunotherapy.

Authors:  Ernesto Rossi
Journal:  Hum Vaccin Immunother       Date:  2022-05-31       Impact factor: 4.526

Review 2.  Overcoming Immune Evasion in Melanoma.

Authors:  Kevinn Eddy; Suzie Chen
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

3.  Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma.

Authors:  Walter J Storkus; Deena Maurer; Yan Lin; Fei Ding; Anamika Bose; Devin Lowe; Amy Rose; Melissa DeMark; Lilit Karapetyan; Jennifer L Taylor; Manoj Chelvanambi; Ronald J Fecek; Jessica N Filderman; Timothy J Looney; Lauren Miller; Elizabeth Linch; Geoffrey M Lowman; Pawel Kalinski; Lisa H Butterfield; Ahmad Tarhini; Hussein Tawbi; John M Kirkwood
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 12.469

4.  Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma.

Authors:  Chao-Ji Shi; Sheng-Ming Xu; Yong Han; Rong Zhou; Zhi-Yuan Zhang
Journal:  Melanoma Res       Date:  2021-12-01       Impact factor: 3.599

5.  Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Based on Cytolytic Activity in Skin Cutaneous Melanoma.

Authors:  Haoxue Zhang; Yuyao Liu; Delin Hu; Shengxiu Liu
Journal:  Front Oncol       Date:  2022-03-08       Impact factor: 6.244

6.  Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.

Authors:  Ernesto Rossi; Ilaria Grazia Zizzari; Alessandra Di Filippo; Anna Acampora; Monica Maria Pagliara; Maria Grazia Sammarco; Maurizio Simmaco; Luana Lionetto; Andrea Botticelli; Emilio Bria; Paolo Marchetti; Maria Antonietta Blasi; Giampaolo Tortora; Giovanni Schinzari; Marianna Nuti
Journal:  Hum Vaccin Immunother       Date:  2022-03-08       Impact factor: 4.526

Review 7.  Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.

Authors:  Ho-Seok Sa; Claire Daniel; Bita Esmaeli
Journal:  J Ophthalmic Vis Res       Date:  2022-08-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.